XenoPort's PD drug disappoints, failing next to Sinemet
This article was originally published in Scrip
Executive Summary
XenoPort said that preliminary top-line results from 28 evaluable patients in a Phase II trial of its investigational Parkinson’s agent XP21279 (sustained-release transported prodrug of levodopa) plus carbidopa did not met the primary endpoint and showed no difference from a standard drug. XenoPort has aimed to show that the co-formulated product, designed for sustained release, can reduce the fluctuations of levodopa in the bloodstream compared to the standard of care, Sinemet (immediate-release levodopa/carbidopa).